Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for High Risk Oral Intra-Epithelial Neoplasias
NCT02882282Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Oral intraepithelial neoplasia (OIN), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
Oral intraepithelial neoplasia (OIN)
Beyond the preview
Go deeper on NCT02882282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882282.